Gain Therapeutics, Inc.
GANX
$2.12
-$0.05-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 23.32% | 94.60% | 8.72% | -38.17% | -10.04% |
| Gross Profit | -23.32% | -94.60% | -8.72% | 38.17% | 10.04% |
| SG&A Expenses | 21.46% | 0.56% | 5.58% | -37.28% | 12.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.40% | 34.15% | 7.40% | -37.76% | -0.13% |
| Operating Income | -22.40% | -34.15% | -7.40% | 37.76% | 0.13% |
| Income Before Tax | -22.49% | -36.89% | -5.82% | 30.39% | -10.90% |
| Income Tax Expenses | 82.19% | -86.11% | 4,893.64% | 11,666.67% | 405.03% |
| Earnings from Continuing Operations | -23.81% | -20.42% | -17.81% | 28.66% | -12.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.81% | -20.42% | -17.81% | 28.66% | -12.85% |
| EBIT | -22.40% | -34.15% | -7.40% | 37.76% | 0.13% |
| EBITDA | -22.46% | -34.06% | -7.39% | 37.80% | 0.16% |
| EPS Basic | 15.90% | 11.76% | 10.70% | 54.81% | 29.29% |
| Normalized Basic EPS | 16.79% | -0.27% | 19.73% | 55.89% | 30.53% |
| EPS Diluted | 15.90% | 11.76% | 10.70% | 54.81% | 29.29% |
| Normalized Diluted EPS | 16.79% | -0.27% | 19.73% | 55.89% | 30.53% |
| Average Basic Shares Outstanding | 47.22% | 36.50% | 31.91% | 57.90% | 59.55% |
| Average Diluted Shares Outstanding | 47.22% | 36.50% | 31.91% | 57.90% | 59.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |